嵌合抗原受体T细胞治疗原发性肝癌的研究进展

Research progress of chimeric antigen receptor T cells in the treatment of primary liver cancer

CAR-T技术作为免疫治疗的一种,从最早期的第一代发展至目前的第4代,其细胞毒性和抗肿瘤免疫效应大大增强,但也暴露出相关安全问题,其在原发性肝癌治疗的相关研究中展现出一定优势,预示着在精准个体化肝癌治疗时代,免疫治疗尤其CAR-T技术联合手术治疗、放化疗和局部治疗等综合治入将会发挥更强有力的作用。

CAR-T technology as a kind of immunotherapy,from the earliest generation of the first to the current fourth generation,its cytotoxic,anti-tumor immune effect greatly enhanced,but also challenged by safety issues.It shows a certain advantage in the therapy of Hepatocellular carcinoma.It indicates that the era of precise individualized liver cancer treatment,immune therapy,especially CAR-T technology combined with surgery,radiotherapy and chemotherapy,local treatment and other comprehensive treatment will play a more powerful role.